Project: A low-cost intranasal vaccine that offers universal protection against pneumococcal infections.

PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will consist of Outer Membrane Vesicles (OMVs), displaying fragments of novel conserved protein antigens. These antigens will warrant universal protection against all pneumococcal serotypes and can be delivered via intranasal administration. If successful, this next-generation vaccine will be able to decrease the incidence of pneumococcal diseases worldwide.

Acronym PNEUMONAV (Reference Number: 9285)
Duration 01/07/2015 - 01/02/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 2

Project partner

Number Name Role Country
20160 Drug Discovery Factory B.V. Coordinator Netherlands
20161 Abera Bioscience AB Partner Sweden
20162 Biotechpharma Partner Lithuania
20163 Medspray BV Partner Netherlands
20164 Vivo Science GmbH Partner Germany
20165 Radboud University Medical Center Partner Netherlands